a2

4. (Amended) The method of claim 1 wherein the vessel has at least [one flexible] two walls with one wall being more deformable than the other wall.

a3

6. (Amended) The method of claim 1 wherein each of the particles [having] has a [mean] volume of between about 5×10^{-24} m^3 to about 5×10^{-6} m^3.

7. (Amended) The method of claim 1 wherein the [substantial binding of the] particles [results at least in part from the particles having a coating] are coated.

a4

10. (Amended) The method of claim 1 wherein the coating comprises a polycationic polymer.

12. (Amended) The method of claim 1 wherein the [network comprises] particles comprise a primary antibody and the additive comprises a secondary antibody, [where] the primary antibody [has] having a substantial binding to [the] a surface component of the cells, and the secondary antibody [has] having a substantial binding to the primary antibody.

a5

13. (Amended) The method of [claim] any of claims 1 – 12 wherein the cells predominantly comprise red blood cells.

14. (Amended) The method of [claim] any of claims 1 – 12 wherein the [sample includes] blood cells comprise white blood cells and platelets.

15. (Amended) The method of any of claims 1 – 12, further comprising measuring [PSA] prostate specific antigen.

16. (Added) The method of claim 1, further comprising measuring creatinine.

17. (Amended) The method of any of claims 1 – 12 wherein at least 70% by volume of the [theoretically available] cell depleted portion is separated from the network within ten minutes.

a6

21. (Amended) The method of any of claims 1 – 12 wherein at least 90% by volume of the [theoretically available] cell depleted portion is separated from the network within ten minutes, with a separation efficiency of at least 95%.